Raymond James Institutional Investors Conference Presentation

CREA TI NG CLA RITY

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Innovation-driven Growth

+ Significant global testing opportunity that drives veterinary medical services ($45B+ TAM)

+ Innovation-driven growth strategy

+ Multiple new-to-the-world platforms in both Point of Care, and disease states like oncology

+ Leveraging installed base with menu extensions and expansions

+ Vertical SaaS & AI enablement

+ Accelerated commercial reach with international focus

+ Long-term durable 10%+ organic revenue growth potential with high ROIC

Integrated Solution Set Delivers Exceptional Customer Value

0

Electronic Medical Records Metrics and Insights

Pet Owner Engagement Clinical Workflow

Significant Global Expansion of CAG Dx Recurring Revenues

CAG Diagnostics Recurring Organic Revenue CAGRs1

Organic Revenue CAGR1

($ Billions)

10%

13%

International

U.S.

2015 - 2020

15%

12%

2020 - 2025

12%

10%

1 Non-GAAP financial measure, please refer to Appendix for descriptive footnotes.

Commercial Expansions & Innovation Driving International Growth

International CAG Diagnostics Recurring Revenue and Organic Growth CAGRs1 ($B)

International Premium Instrument Installed Base*

$1.2B

12%

CAGR

$0.7B

13%

CAGR

IDEXX

inVue Dx

Urinalysis

Hematology

Chemistry

1 Non-GAAP financial measure, please refer to Appendix for descriptive footnotes.

© 2026 IDEXX Laboratories, Inc. All rights reserved.

*All figures are rounded. Premium chemistry includes IDEXX Catalyst Dx and Catalyst One Chemistry Analyzers. Premium hematology includes ProCyte Dx

, ProCyte One , and LaserCyte Hematology Analyzers. Premium

Urinalysis includes SediVue Dx

Urine Sediment Analyzer. 6

IDEXX U.S. Growth has Outpaced Sector Growth

IDEXX U.S. CAG Dx Recurring Revenue Organic Growth and

U.S. Sector Revenue Growth per Practice

(2020 - 2025 CAGR)

Clinical

+0.3%

IDEXX U.S. CAG Dx

Recurring Revenue Organic Growth1

Total Visits

Per Practice

Total Revenue

Per Practice

Clinical Revenue

Per Practice

Diagnostics Revenue

Per Practice

1 Non-GAAP financial measure, please refer to Appendix for descriptive footnotes.

Source: Analysis based on IDEXX Practice Intelligence data n = ~8,000 practices. Clinical revenue is associated with clinical visits, where the reason for visit involves an interaction between a veterinary clinician and a pet, including wellness and non-wellness visit types.

Pets are Living Appreciably Longer - Benefiting Diagnostics

Average Patient Lifespan 2010 - 2024*

14.4

+ 22% increase

in lifetime diagnostic spend per patient**

13.4

12.3

11.6

* Based on an analysis of IDEXX Practice Intelligence data from 2 million canine and feline patients with recorded deaths from 2010 through 2024. Lifespan reflects median patient age at time of death.

**Assuming constant annual spend per-patient, by age cohort over the full period.

Diagnostic Spend Rises with Age - Significant Headroom to Grow

Top Third of Practices Use ~1.5X More Diagnostics Than the Peer Average

U.S. Average Annual Practice Diagnostic Revenue Per Active Patient by Age Segment*

Top Third of Practices, based on clinical bloodwork usage**

All U.S.

Practices

Puppies & Kittens Young

(1 to 3 years)

Adult

(3 to 7 years)

Senior

(7 to 11 years)

Geriatric

(11 years and Over)

*Analysis based on 2024 IDEXX Practice Intelligence data (n = ~7,500 practices), weighted to be representative of the U.S based on practice size and region. Average annual diagnostic revenue includes wellness and non-wellness utilization.

**Top third of practices defined based on percentage of clinical visits that include bloodwork.

Estimates are for the overall number of active patients by age segment, not specifically for those receiving diagnostics. Revenue figures are rounded to the nearest $5.

Step-up in Pet Population Creates More Care Opportunities

U.S. Pet Population and Annual Growth*

~3%

CAGR

~12%

~0%

~1%

~1% historical growth

Pandemic period ~12% growth

Long-term outlook ~1% growth

*Estimated U.S. pet population growth of based primarily on modeling of dog and cat population growth leveraging analyses of multiple data sources.

Expanding Investment Drives Accelerated Pace of Innovation

IDEXX Cumulative R&D Investment

Areas of Expertise > $2.4 Billion

$1.2B

(20 years)

$1.2B

(7 years)

$1.2B

(4+ years)

Instrument Platforms

Differentiated Assays

Software, Data, AI and Connectivity ~$3.5B

Opportunity*

Parasitology

Innovation Focus Aligned with Significant Testing Opportunities

>$1B

Opportunity*

~$4B

Opportunity*

~$2.5B

Opportunity*

Screening Tests for More Accurate Disease Detection

Fecal Antigen Testing for Earlier and More

Comprehensive Detection

Testing for Kidney Impairment and Injury, Identifies Targeted Treatment

Testing for Early Onset of Cancer

*Total addressable revenue opportunity estimated based on bottom-up modeling at manufacturer or service provider level. Assumes current proportion of household-owned dogs and/or cats visiting the veterinary practice for wellness and/or non-wellness visits and estimated average manufacturer revenue for appropriate diagnostics used in each type of visit. Note that these global opportunities are estimated as of 2023 and are anticipated to grow over time based on the known underlying drivers, e.g., clinical visit growth per practice, net new practice formation and net price realization.

Transforming Real-time Insights at the Point of Care

2014

2016 2020

2024

Future

IDEXX SmartService

Catalyst One

SediVue Dx

ProCyte One

IDEXX

inVue Dx

IDEXX

MultiCue Dx

Technology for Life

Trusted Accuracy

Reference lab quality

Load and Go

Low effort sample prep

End-to-End Integration

Optimized workflow

IDEXX inVue Dx Advances Large Cytology Categories

Launched Menu

Future Opportunity

Ear Cytology

Blood Morphology

~50M

Launched menu cytologies

done annually*

Fine Needle Aspirates

100M+

Other in-clinic cytologies

done annually**

*FNA, blood morphology, and ear cytology annual estimate based on analysis of multiple data sources including IDEXX U.S. data on file

**Symptoms, Causes, Treatment, and Prevention; American Kennel Club 2023, and Ear Mites: Uncovering, Treating, and Preventing Infestations, Today's Veterinary Practice, 2021

Platform Extensibility Key to Economic Value Expansion

IDEXX Instrument Economic Value (EV)*

2.5x

Expansion**

+ New Menu

+ Utilization

Menu Expansion

Launch Menu

Future Expansion

+ New Menu

+ Utilization

Near-term EV

+ Ear Cytology

+ Blood Morphology

+ FNA 'Lumps and Bumps'

Catalyst IDEXX inVue Dx

*Economic Value represents cumulative 7-year gross profit generated by an instrument placement from the instrument, consumables, service and accessories. Catalyst EV is global average for Catalyst Dx and Catalyst One.

**Catalyst EV expansion represents the increase in EV between year-end 2014 and 2024.

Long Runway to Expand Premium Installed Base Over 3X

Global IDEXX Premium Instrument Installed Base*

Global Incremental IDEXX Premium Instrument Placement Opportunity**

90k ~387k

165k

~6,400

IDEXX inVue Dx

Urinalysis Hematology

Chemistry

66k

83k

64k

84k

International

U.S.

2025

Total

Catalyst ProCyte

SediVue Dx

inVue Dx

MultiCue Dx

*All figures are rounded. Premium chemistry includes IDEXX Catalyst Dx

and Catalyst One Chemistry Analyzers. Premium hematology includes ProCyte Dx , ProCyte One , and LaserCyte Hematology Analyzers. Premium Urinalysis includes SediVue Dx Urine Sediment Analyzer.

**All figures are rounded. Excludes practices too small to be likely candidates for chemistry analyzer placement at this time. Second placement opportunities are excluded.

IDEXX Cancer Dx: High Performance Oncology Platform

Canine Lymphoma Mast Cell Tumors

+ 79% sensitivity & 99%+ specificity

+ B-cell versus T-cell phenotyping

+ Detects lymphoma signal up to 8 months prior to clinical manifestation

+ CHOP chemotherapy monitoring

+ Joins the panel at no additional cost mid-year 2026 and with no change to sample requirements or workflow

Diagnostics platform that will expand to cover 50%+ of canine cancers

+ With MCT and Lymphoma, IDEXX Cancer Dx will detect over 1/3 of canine cancer cases, with one additional cancer type later in 2026

Addition of Cancer Screening Will Inspire Broader Dx Inclusion

Preventive Healthcare Today… …and with the next chapter

Physical Examination

Clinical History

Diagnostic Testing

Vector Borne Disease

Fecal Testing

Complete Blood Count

Chemistry, Electrolytes, SDMA

Cancer Screening

Current Dx inclusion rates

47%* 12%**

IDEXX Cancer Diagnostics included in a preventive care panel for at-risk dogs

*Percentage of U.S. wellness clinical visits with at least one in-house or reference laboratory diagnostic test, excluding radiography, in 2024

**Percentage of U.S. wellness clinical visits with bloodwork (chemistry and / or hematology testing) in 2024

Source: Based on an analysis of IDEXX Practice Intelligence data from ~2,200 to 4,700 practices. Clinical visits are those where the reason for visit involves an interaction between a veterinary clinician and a pet, including wellness and non-wellness visit types. Percentages rounded to the nearest 1%.

Pet Parents, Veterinarians Want Early Cancer Detection

Veterinarians

Likelihood to Include Cancer in Wellness Screening

Source: Quantitative Veterinarian Research, International Fieldwork in November and December 2024 (n = 1,264 veterinarians).

Source: Quantitative Dog Owner Research, U.S. Fieldwork in May 2024, International Fieldwork December 2024 (n = 1,730 dog owners).

% of veterinarians 'very' or 'somewhat' likely to add cancer to wellness

Pet Parents

% of dog owners 'very' or 'somewhat' likely to agree to cancer screen

Comprehensive Software Platform for Animal Health

SOAP Notes

Personalization

Decision Support

Personalized Financing

AI Enabled

© 2026 IDEXX Laboratories, Inc. All rights reserved.

20

© 2026 IDEXX Laboratories, Inc. All rights reserved.